Provided by Tiger Trade Technology Pte. Ltd.

Rite Aid

0.6483
0.0000
Volume:- -
Turnover:1.70M
Market Cap:35.78M
PE:-0.04
High:0.6483
Open:0.6483
Low:0.6483
Close:0.6483
52wk High:7.37
52wk Low:0.3779
Shares:55.19M
Float Shares:54.03M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.2436
EPS(LYR):-13.7150
ROE:-2628.85%
ROA:0.08%
PB:-0.04
PE(LYR):-0.05

Loading ...

T RAD Co Sees FY Net Y8.70B

Dow Jones
·
Feb 02

C-RAD Names Former Biotage Chief Tomas Blomquist as CEO to Drive Next Growth Phase

TIPRANKS
·
Jan 26

RAD Increases Ownership in Radiopharm Ventures to 87.5%

GlobeNewswire
·
Jan 12

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

GlobeNewswire
·
Dec 15, 2025

Radius Residential Care Limited (NZSE:RAD) Stock Goes Ex-Dividend In Just Four Days

Simply Wall St.
·
Nov 29, 2025

Radius Residential Care Limited's (NZSE:RAD) Stock Is Going Strong: Have Financials A Role To Play?

Simply Wall St.
·
Nov 21, 2025

BUZZ-New Zealand's Radius Residential Care hits near 4-month high on strong HY results

Reuters
·
Nov 19, 2025

BRIEF-Radius Residential Care Declares Interim Cash Dividend Of 1.0 NZ Cent Per Share

Reuters
·
Nov 19, 2025

Radius Residential Care - Expects 2H26 Trading to Be Broadly Consistent With H1

THOMSON REUTERS
·
Nov 19, 2025

Radius Residential Care H1 Adjusted Ebitda Nzd 14.9 Million

THOMSON REUTERS
·
Nov 19, 2025

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

GlobeNewswire
·
Nov 18, 2025

Radiopharm Theranostics Gains Approval for Phase 1 Trial of RAD 402 in Prostate Cancer

TIPRANKS
·
Nov 18, 2025

Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

GlobeNewswire
·
Nov 17, 2025

Artificial Intelligence Technology Solutions Secures Major RAD Order

TIPRANKS
·
Nov 17, 2025

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

GlobeNewswire
·
Nov 12, 2025

T RAD Co Raises FY Net View to Y6.40B

Dow Jones
·
Nov 04, 2025

Artificial Intelligence Technology Solutions Secures Major RAD Contract

TIPRANKS
·
Nov 03, 2025

C-RAD AB Announces Share Repurchase Program to Optimize Capital Structure

TIPRANKS
·
Oct 23, 2025

C-RAD AB Reports Strong Q3 2025 Earnings and Strategic Growth Initiatives

TIPRANKS
·
Oct 22, 2025

C-RAD Announces Leadership Transition with New Acting CEO

TIPRANKS
·
Oct 22, 2025